Skip to main content
Journal ArticleOPEN ACCESS

A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)

  • Hoimes C
  • Albany C
  • Hoffman-Censits J
  • et al.
Annals of Oncology (2018) 29 viii726
DOI: 10.1093/annonc/mdy424.039
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Pembro is FDA and EMA approved for metastatic UC and may improve response rates in the locally advanced setting when combined with gemcitabine (G) a

Cite

CITATION STYLE

APA

Hoimes, C. J., Albany, C., Hoffman-Censits, J., Fleming, M. T., Trabulsi, E., Picus, J., … Kaimakliotis, H. (2018). A phase Ib/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC). Annals of Oncology, 29, viii726. https://doi.org/10.1093/annonc/mdy424.039

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free